indication

Early Course Schizophrenia Spectrum Disorder

Competitive landscape projected to CVL-562 (PF-06412562) 25 mg’s launch window

as of 2026-07-01
Competitive set
0
0 approved · 0 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
1 events
2024
2026
2028
2030
today
CVL-562 (PF-06412562) 25 mg launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
Nothing in the set matches — the product only shows what’s in the data.

Market size

prevalence as a range, not a number